Nitmed Biotech

Nitmed Biotech is a clinical-stage biotechnology company specializing in the development of innovative Nitric Oxide (NO) based therapeutics. The company leverages a proprietary controlled-release platform to deliver gas-signal molecules for the treatment of chronic wounds and various vascular conditions. Its lead candidate, NT-101, is currently in Phase 2 clinical trials for the treatment of diabetic foot ulcers, utilizing the antimicrobial and pro-angiogenic properties of nitric oxide to promote healing. Nitmed's technology addresses significant unmet needs in regenerative medicine by providing stable and localized delivery of therapeutic gases. Headquartered in Suzhou, China, the company continues to expand its pipeline into dermatology and cardiovascular indications.